Effectiveness of pioglitanone hydrochloride on cerebral vasospasm after subarachnoid hemorrhage (SAH)
Not Applicable
Not yet recruiting
- Conditions
- subarachnoid hemorrhage
- Registration Number
- JPRN-UMIN000002768
- Lead Sponsor
- Tokyo Womens Medical University Medical Center East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
old person over 90 year-old, medicine hypersensitivity patient, pregnant woman or woman who has pregnancy possibly, hypoglycemia, person who was judged inadequat as patient by doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method functional prognosis (modified-Ranking Scale), evaluation of vasospasm by angiography, evaluation of cerebral infarction by CT or MRI
- Secondary Outcome Measures
Name Time Method evaluation of adverse reaction
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pioglitazone's effect on cerebral vasospasm after subarachnoid hemorrhage?
How does pioglitazone compare to calcium channel blockers in preventing delayed cerebral ischemia post-SAH?
Are there specific biomarkers that predict response to pioglitazone in patients with aneurysmal subarachnoid hemorrhage?
What are the potential adverse events associated with pioglitazone use in acute stroke patients and how are they managed?
What other PPAR-gamma agonists or combination therapies show promise in treating cerebral vasospasm following subarachnoid hemorrhage?